Related Experiment Video
Updated: Oct 16, 2025
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
691
Diffuse goitre enlargement after immunotherapy for non-small cell lung cancer
Kohei Fujita1, Norio Araki2, Tadashi Mio1
1Division of Respiratory Medicine, Center for Respiratory Diseases National Hospital Organization Kyoto Medical Center Kyoto Japan.
Respirology Case Reports
|October 20, 2021
Summary
Hyperprogressive disease (HPD) can occur during immune checkpoint inhibitor therapy. This case highlights HPD in metastatic thyroid cancer, emphasizing the need for clinical vigilance due to its potentially life-threatening nature.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Immune checkpoint inhibitors (ICIs) are a cornerstone of cancer therapy.
- Hyperprogressive disease (HPD) is a recognized, albeit rare, adverse event associated with ICI treatment.
- The occurrence of HPD in thyroid cancer during immunotherapy requires further investigation.
Purpose of the Study:
- To report a rare case of hyperprogressive disease (HPD) in a patient with metastatic thyroid cancer receiving immunotherapy.
- To underscore the clinical significance and potential life-threatening implications of HPD in this specific cancer type.
- To raise awareness among clinicians regarding HPD during ICI therapy for thyroid malignancies.
Main Methods:
- Case report detailing a patient with metastatic thyroid cancer undergoing immunotherapy.
- Clinical observation and documentation of disease progression.
- Review of relevant literature on hyperprogressive disease and thyroid cancer immunotherapy.
Main Results:
- The patient developed hyperprogressive disease (HPD) during treatment with immune checkpoint inhibitors.
- The observed HPD in metastatic thyroid cancer presented a significant clinical challenge.
- The rapid progression of the tumor highlighted the potential severity of HPD.
Conclusions:
- Hyperprogressive disease (HPD) is a critical consideration in patients with metastatic thyroid cancer receiving immunotherapy.
- Clinicians must maintain a high index of suspicion for HPD and monitor patients closely.
- Early recognition and management strategies for HPD are crucial for patient outcomes in thyroid cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
740
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
740
01:23The Thyroid Gland
4.8K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
4.8K